Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [839]

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable...

Dr Ian Krop - Yale Cancer Center, Connecticut, USA

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previously treated with T-DM1 ( Dr Ian Krop - Yale Cancer Center, Connecticut, USA )

ASH 2022: Multiple myeloma roundup

Dr Thomas Martin - UCSF Medical Centre, San Francisco, USA

ASH 2022: Multiple myeloma roundup ( Dr Thomas Martin - UCSF Medical Centre, San Francisco, USA )

Gemtuzumab ozogamicin plus chemotherapy improves outcomes in intermediate-risk...

Dr Eunice Wang - Roswell Park Comprehensive Cancer Center, New York, USA

Gemtuzumab ozogamicin plus chemotherapy improves outcomes in intermediate-risk cytogenetic AML ( Dr Eunice Wang - Roswell Park Comprehensive Cancer Center, New York, USA )

Talquetamab: Robust efficacy and manageable safety for heavily pretreated R/R...

Dr Ajai Chari - Mount Sinai School of Medicine, New York, USA

Talquetamab: Robust efficacy and manageable safety for heavily pretreated R/R multiple myeloma ( Dr Ajai Chari - Mount Sinai School of Medicine, New York, USA )

What is required to advance data ethics, data sharing, and Open Science across...

Dr Priya Kumari - Regional Cancer Centre Trivandrum, Trivandrum, India

What is required to advance data ethics, data sharing, and Open Science across LMICs ( Dr Priya Kumari - Regional Cancer Centre Trivandrum, Trivandrum, India )

Acalabrutinib, venetoclax and obinutuzumab show high rates of clinical response...

Dr Christine Ryan - Dana-Farber Cancer Institute, Boston, USA

Acalabrutinib, venetoclax and obinutuzumab show high rates of clinical response in previously untreated CLL enriched for high-risk disease ( Dr Christine Ryan - Dana-Farber Cancer Institute, Boston, USA )

Adjuvant endocrine therapy +/- 1 year of everolimus fails to improve iDFS and...

Dr Mariana Chavez Mac Gregor - MD Anderson Cancer Center, Houston, USA

Adjuvant endocrine therapy +/- 1 year of everolimus fails to improve iDFS and OS in patients with high-risk HR+, HER2-negative BC ( Dr Mariana Chavez Mac Gregor - MD Anderson Cancer Center, Houston, USA )

Treatment decision guided by CTC count may improve long-term outcomes for mBC

Prof Jean-Yves Pierga - Institut Curie, Paris, France

Treatment decision guided by CTC count may improve long-term outcomes for mBC ( Prof Jean-Yves Pierga - Institut Curie, Paris, France )

Genomic testing: Australian model for unlocking the potential of precision...

Prof David Thomas - The Garvan Institute of Medical Research, Darlinghurst...

Genomic testing: Australian model for unlocking the potential of precision oncology for patients and health systems ( Prof David Thomas - The Garvan Institute of Medical Research, Darlinghurst, Australia )

Xevinapant plus standard of care chemoradiotherapy improved 5 year OS for...

Prof Jean Bourhis - University Hospital of Lausanne, Lausanne, Switzerland

Xevinapant plus standard of care chemoradiotherapy improved 5 year OS for unresected LA SCCHN ( Prof Jean Bourhis - University Hospital of Lausanne, Lausanne, Switzerland )

Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced...

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA

Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )

Cancer survivors' stories: An African perspective

Dr Zainab Shinkafi-Bagudu - Founder of the Medicaid Cancer Foundation

Cancer survivors' stories: An African perspective ( Dr Zainab Shinkafi-Bagudu - Founder of the Medicaid Cancer Foundation )

More from ecancer